Sanofi stock gains as Cheplapharm deal and Deutsche Bank Buy rating shape outlook

Published on 09/15/2026 at 15:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock closed at EUR 74.96 on Euronext Paris on September 14, 2026, up 2.32 percent after a strategic deal with Cheplapharm. Deutsche Bank keeps Sanofi stock at Buy with a EUR 95 price target as of September 15, 2026.

Schwarzweiß-Reportagefoto einer Newsroom-Redaktion mit Blick auf Paris — Vivendi SE (FR0000127771) zählt zu Frankreichs Medienkonzernen; die Schwarzweiß-Reportage zeigt eine Pariser Redaktion, Illustration mit AI erstellt.

Sanofi stock (ISIN FR0000127771) finished trading on Euronext Paris at EUR 74.96 on September 14, 2026, up 2.32 percent from the prior close and outperforming the CAC 40 index on the same day. As GlobeNewswire reported on September 14, 2026, Sanofi has announced a strategic partnership with Cheplapharm to transfer 20 mature medicines and three manufacturing sites, while taking a 26.4 percent equity stake in the German group, with the company stating that the transaction will not affect its 2026 financial guidance.GlobeNewswire According to MarketScreener data dated September 15, 2026, analyst Emmanuel Papadakis at Deutsche Bank continues to rate Sanofi stock as Buy with a price target of EUR 95, implying a notable upside versus the current share price.MarketScreener

Cheplapharm partnership refocuses Sanofi on innovation

As detailed in Sanofi's press release from Paris on September 14, 2026, the company plans to transfer a portfolio of 20 mature medicines and three manufacturing sites located in Hungary, Singapore and France to Cheplapharm, a specialist in well-established medicines, in exchange for a 26.4 percent equity stake.GlobeNewswire According to the same release, the commercial transfer of the medicine portfolio is scheduled to begin in the first quarter of 2027, with the full transaction expected to be completed by the third quarter of 2027, and Sanofi highlighted that the deal is not expected to have any impact on its financial guidance for 2026.GlobeNewswire

Further context on the strategic shift is provided by a Bloomberg report dated September 14, 2026, which notes that Sanofi's new chief executive officer is using the divestment of older medicines to focus the company more squarely on innovative products, handing over mature medicines and three manufacturing sites to Cheplapharm while securing the 26.4 percent equity stake.Bloomberg TipRanks also highlights that key brands such as anticoagulant Lovenox/Clexane are among the medicines to be transferred, with commitments by Cheplapharm to preserve jobs and specialized manufacturing skills, while reiterating that Sanofi expects the financial impact of the deal to be neutral for its 2026 guidance.TipRanks

Analyst stance and portfolio ambitions

For investors, the analyst perspective is a key part of the Sanofi story around mid-September 2026. According to MarketScreener on September 15, 2026, Deutsche Bank's analyst Emmanuel Papadakis maintains a Buy rating on Sanofi with an unchanged price target of EUR 95, at a time when the shares are trading around EUR 74.5 to EUR 75 on Euronext Paris, suggesting potential upside of more than 20 percent if the target were reached.MarketScreener A separate analysis reported by finanzen.ch on September 15, 2026 reiterates the Deutsche Bank Research view, noting the Buy rating and EUR 95.00 price target while pointing out that the current market price remains significantly below that level, thereby underlining Deutsche Bank's constructive stance on Sanofi stock.finanzen.ch

Beyond near-term rating details, Regeneron Pharmaceuticals' comments about the joint product Dupixent underline Sanofi's longer-term revenue ambitions. As finance content on Yahoo noted on September 15, 2026, Regeneron highlighted that it and Sanofi are targeting broader global access for Dupixent after Sanofi raised its 2030 sales forecast to EUR 25 billion, positioning the drugmaker for growth in specialty care over the rest of the decade.Yahoo Finance That long-term revenue target serves as a backdrop to the current restructuring of the mature medicines portfolio, suggesting that Sanofi seeks to streamline legacy assets while concentrating capital and management attention on high-growth franchises led by Dupixent and other innovative therapies.

Risk signals around TZIELD and regulatory scrutiny

In parallel with its strategic portfolio moves, Sanofi also faces regulatory scrutiny on specific products. According to Newsquawk's European equity opening news dated September 15, 2026, Health Canada has issued an alert for Sanofi's autoimmune therapy TZIELD after serious and life-threatening cases of viral reactivation were observed, leading the regulator to contraindicate TZIELD in patients with active viral infections, any active serious infection or those who are immunocompromised.Newsquawk While the financial implications of this safety communication are not quantified in the available sources, the development underscores the typical risk profile of innovative biopharmaceutical pipelines, where regulatory decisions on individual products can influence investor sentiment even as broader portfolio strategies are focused on long-term growth.

Sanofi stock level on Euronext Paris

Sanofi stock closed at EUR 74.96 on Euronext Paris on September 14, 2026, compared with a prior close of EUR 73.26, corresponding to a daily gain of 2.32 percent and a move that left the shares ahead of the broader Paris market, where the CAC 40 index fell 0.76 percent to 8,117.78 points on the same day.Ad hoc corporate news In early trading on September 15, 2026, real-time data snapshots referenced by MarketScreener show Sanofi shares around EUR 74.47 to EUR 74.58 on Euronext Paris, modestly lower than the previous close, which positions the stock below the EUR 95 price target maintained by Deutsche Bank and below the long-term sales ambitions that Sanofi has set for 2030.MarketScreener